Huntington National Bank’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Huntington National Bank’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-38	Closed	-$1K	–	1761
2016 Q1	$1K	Buy	+38	New	+$731	﹤0.01%	1698
2015 Q2	–	Sell	-38	Closed	-$1K	–	1854
2015 Q1	$1K	Hold	38	–	–	﹤0.01%	1710
2014 Q4	$1K	Buy	+38	New	+$1.04K	﹤0.01%	1713
2014 Q1	–	Sell	-38	Closed	-$2K	–	1672
2013 Q4	$2K	Hold	38	–	–	﹤0.01%	1660
2013 Q3	$2K	Hold	38	–	–	﹤0.01%	1683
2013 Q2	$2K	Buy	+38	New	+$1.9K	﹤0.01%	1667

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Huntington National Bank's NAVB Position: Q2 2016 in Review

Huntington National Bank sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2016, closing a stake of 38 shares — an estimated $1K sold.

Huntington National Bank first reported a position in NAVB in Q2 2013 and held it in 6 quarters. The position peaked at $2K in Q4 2013. 63 funds tracked by Wall St. Rank hold NAVB as of Q2 2016.

Huntington National Bank reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2016 after selling out during the quarter.
Huntington National Bank sold 38 Navidea Biopharmaceuticals Inc. shares in Q2 2016, an estimated $1K.
Huntington National Bank first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 6 quarters.
Huntington National Bank's Navidea Biopharmaceuticals Inc. position peaked at $2K in Q4 2013.
63 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2016.

Based on Huntington National Bank's 13F filing for Q2 2016, filed 25 Jul 2016.